NEWS!
RESPIRERX PHARMACEUTICALS INC. SEND NOTICE LETTER TO THE BOARD OF DIRECTORS OF THERAPIX BIOSCIENCES LTD.
BY GlobeNewswire
— 9:00 AM ET 07/30/2019
Glen Rock, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ( RSPI ) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the treatment of sleep-related breathing disorders, announces that it has sent a formal notice to the Board of Directors of Therapix Biosciences Ltd. (Therapix).
In public disclosures on the Therapix’ website and in its press releases (most recently on July 23, 2019), Therapix has repeatedly made public statements that it intends to develop THX-110, a combination of dronabinol and PEA, for treating obstructive sleep apnea (OSA) in the United States and other markets.
RespireRx Pharmaceuticals Inc ( RSPI ) has licensed and is in possession of patents and patent applications for treating any sleep related breathing disorder, including OSA, using any cannabinoid alone or in combination with any other molecule or drug.
Our existing patents and IP assets in development for related formulations and drug combinations, expressly exclude all use, production, sale or offer for sale of Therapix’s proposed THC/PEA combination for OSA.
To the extent Therapix violates RespireRx’s patent rights, anywhere in the world where these patents are applicable, we will vigorously enforce these rights, including through formal litigation with Therapix and against any of its affiliates, successors or assigns who may collaborate with Therapix to violate our intellectual property rights.
This press release constitutes notice to all interested parties that RespireRx objects to Therapix’s repeated public announcements of a development plan for dronabinol/PEA for OSA and that these announcements are believed to constitute cause for immediate legal action to remedy Therapix’s continuing, repeated interference with RespireRx’s business practices.
We trust Therapix will dutifully comply with its obligations to advise all prospective partners, investors, shareholders and responsible regulatory authorities of the material content of this press release.
